In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer

Cancer Research

Volumn 69, Issue 24, 2009, Pages 9376-9384

  Ugel, Stefano ^a   Zoso, Alessia ^b,d   De Santo, Carmela ^a,e   Li, Yu ^b   Marigo, Ilaria ^a   Zanovello, Paola ^a   Scarselli, Elisa ^c   Cipriani, Barbara ^c   Oelke, Mathias ^b   Schneck, Jonathan P ^b   Bronte, Vincenzo ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Istituto di Ricerche di Biologia Molecolare   (Italy)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; DIMER; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN; MAJOR HISTOCOMPATIBILITY ANTIGEN; RECOMBINANT INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TYROSINASE RELATED PROTEIN 2;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ARTIFICIAL ANTIGEN PRESENTING CELL; CANCER IMMUNIZATION; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; CYTOLYSIS; FEMALE; IMMUNE RESPONSE; INTRAVENOUS ADMINISTRATION; LUNG METASTASIS; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; THERAPY EFFECT;

ANIMALS; ANTIBODY AFFINITY; ANTIGEN-PRESENTING CELLS; CELL GROWTH PROCESSES; FEMALE; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA, EXPERIMENTAL; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 73649090450     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-0400     Document Type: Article

References (30)

1. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
2. Mocellin S,Mandruzzato S, Bronte V, LiseM, Nitti D. Part I: vaccines for solid tumours. Lancet Oncol 2004;5:681-9.
3. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4.
4. Meidenbauer N, Marienhagen J, Laumer M, et al. Survival and tumor localization of adoptively transferred melan-a-specific T cells in melanoma patients. J Immunol 2003;170:2161-9.
5. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23:2346-57.
6. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic cell defects. Nat Rev Immunol 2004;4:941-52.
7. Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM. Mechanism of immune dysfunction in cancer mediated by immature gr-1(+) myeloid cells. J Immunol 2001;166: 5398-406.
8. Lyman MA, Nugent CT, Marquardt KL, Biggs JA, Pamer EG, Sherman LA. The fate of low affinity tumorspecific CD8+ T cells in tumor-bearing mice. J Immunol 2005;174:2563-72.
9. Woo EY, Yeh H, Chu CS, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002;168:4272-6.
10. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007;117:1155-66.
11. Wang RF, Appella E, Kawakami Y, Kang X, Rosenberg SA. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 1996; 184:2207-16.
12. Bronte V, Apolloni E, Ronca R, et al. Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res 2000;60:253-8.
13. De Palma R, Marigo I, Del Galdo F, et al. Therapeutic effectiveness of recombinant cancer vaccines is associated with a prevalent T-cell receptor α usage by melanoma-specific CD8+ T lymphocytes. Cancer Res 2004;64:8068-76.
14. Seliger B, Ritz U, Abele R, et al. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res 2001;61:8647-50.
15. Slansky JE, Rattis FM, Boyd LF, et al. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 2000;13:529-38.
16. Romero P, Valmori D, Pittet MJ, et al. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev 2002;188:81-96.
17. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic tumor-associated peptide vaccine for the treatment of patientswithmetastatic melanoma. NatMed 1998;4:321-7.
18. Matzinger P. The danger model: a renewed sense of self. Science 2002;296:301-5.
19. Yu P, Lee Y, Liu W, et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 2004;5:141-9.
20. Kaufman HL, Deraffele G, Mitcham J, et al. Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest 2005;115:1903-12.
21. Oelke M, Maus MV, Didiano D, June CH, Mackensen A, Schneck JP. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med 2003;9:619-25.
22. Oelke M, Krueger C, Giuntoli RL II, Schneck JP. Artificial antigen-presenting cells: artificial solutions for real diseases. Trends Mol Med 2005;11:412-20.
23. Oelke M, Schneck JP. HLA-Ig-based artificial antigenpresenting cells: setting the terms of engagement. Clin Immunol 2004;110:243-51.
24. Mennuni C, Ugel S, Mori F, et al. Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer. Cancer Res 2008;68:9865-74.
25. Dal Porto J, Johansen TE, Catipovic B, et al. A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations. Proc Natl Acad Sci U S A 1993;90:6671-5.
26. O'Herrin SM, Slansky JE, Tang Q, et al. Antigenspecific blockade of T cells in vivo using dimeric MHC peptide. J Immunol 2001;167:2555-60.
27. Cullen CM, Jameson SC, DeLay M, et al. A divalent major histocompatibility complex/IgG1 fusion protein induces antigen-specific T cell activation in vitro and in vivo. Cell Immunol 1999;192:54-62.
28. Savage P, Millrain M, Dimakou S, Stebbing J, Dyson J. Expansion of CD8+ cytotoxic T cells in vitro and in vivo using MHC class I tetramers. Tumour Biol 2007;28:70-6.
29. Carey B, DeLay M, Strasser JE, et al. A soluble divalent class I MHC/IgG1 fusion protein activates CD8+ T cells in vivo. Clin Immunol 2005;116:65-76.
30. Johnson LA, Heemskerk B, Powell DJ, et al. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J Immunol 2006;177:6548-59.